Tonix makes two new hires
This article was originally published in Scrip
Executive Summary
Tonix Pharmaceuticals, a US company developing drugs for central nervous system disorders, has appointed Dr Leland Gershell as chief financial officer and Dr Bruce Daugherty in the newly created position as senior director of drug development. Benjamin Selzer, who served as interim chief financial officer, will continue as the company's chief operating officer. Dr Gershell most recently served as managing director and senior analyst at Madison Williams and Company, where he provided research on specialty pharmaceutical and biotechnology companies, while Dr Daugherty has more than 30 years' experience in drug development and scientific research, mostly with Merck & Co, where he most recently served as senior research fellow.